<DOC>
	<DOC>NCT00624351</DOC>
	<brief_summary>The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.</brief_summary>
	<brief_title>Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Positive ANA result at visit 1 Current diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology revised criteria such that at least 4 of the 11 criteria are met Active moderate or severe SLE disease activity as demonstrated by British Isles Lupus Assessment Group (BILAG) A level disease activity in at least one body/organ system or BILAG B level disease activity in at least two body/organ systems if no BILAG A level disease is present If on antimalarials, dose regimen must be stable for 4 weeks prior to study entry. Patients receiving any live vaccination within 2 weeks prior to visit 1 or during the course of the study Active severe SLE disease activity which involves the central nervous system (CNS) (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher World Health Organization (WHO) nephritis) or serum creatinine &gt;2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria &gt;3.5gm/day Patients with a history of antiphospholipid antibody syndrome AND use of oral anticoagulants or antiplatelet treatment Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
</DOC>